HALF: Prospective multi-centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.

• Authors: ŽÁČKOVÁ Daniela; ČIČÁTKOVÁ Petra; FABER Edgar; STEJSKAL Lukáš; KARAS Michal; BĚLOHLÁVKOVÁ Petra; KLAMOVÁ Hana; ČERNÁ Olga; CMUNT Eduard; SEMERÁD Lukáš; HORŇÁK Tomáš; KVETKOVÁ Anežka; PROCHÁZKOVÁ Jiřina; RYCHLÍČKOVÁ Jitka; ŠTĚPÁNOVÁ Radka; SVOBODNÍK Adam; MACHOVÁ POLÁKOVÁ Kateřina; JEŽÍŠKOVÁ Ivana; JURČEK Tomáš; BORSKÝ Marek; VIEWIORKA O.; DEMLOVÁ Regina; MAYER Jiří
• Year of publication: 2022
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligible patients and it can cause burdening TKI withdrawal syndrome (TWS) in about 30% of them. Moreover, any robust clinical or biological factor predictive for successful TFR has not been identified yet. On top of that, sustainable deep molecular response (DMR) as the main prerequisite for TKI discontinuation attempt is achieved only in 20-40% of patients. The majority of CML patients, therefore, need to be treated with the effective and well-tolerated drug for a long time or even life-long.